NVG, LLC

Lobbying for NOVO NORDISK INC. · Pharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $120,000.00 income · posted Jul 20, 2025

Lobbying activity 2

Medicare/Medicaid

Issues related to Medicare coverage of Anti-Obesity Medicines.

Health Issues

Issues related to pharmaceutical supply chain transparency and integrity. Issues related to compounding and counterfeit medicines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.